Our look is new. Our purpose is the same. Learn more about our brand evolution.
MOVE Peds is essential to pave the way by Natalie Katz, MD, and Katy de Valle, research physical therapist More than 50% of people with FSHD develop symptoms as children […]
SOLVE FSHD, a venture philanthropic organization established to catalyze innovation in Facioscapulohumeral muscular dystrophy (FSHD) research, is partnering with the nonprofit organization XPRIZE Foundation to host a global competition to […]
Upper body mobility: A crucial focus in FSHD treatment by Anna Gilmore, FSHD Society On August 23, 2024, the FSHD Society brought a fresh perspective to the Food and Drug […]
Avidity begins Cohort C enrollment in FORTITUDE trial Avidity Biosciences has begun enrollment of Cohort C of the Phase 1/2 FORTITUDE™ clinical trial. Below is Avidity’s letter to the FSHD […]
by Yi-Wen Chen, PhD, Children’s National Hospital, Washington DC Many Nobel Prize-winning discoveries have contributed to the advancement of research and treatments for facioscapulohumeral muscular dystrophy (FSHD), and the work […]
